Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|June 9, 2014
Specialty Medications and Drug Spending
Author(s)Davy James, Associate Editor
Michael Einodshofer, RPh, MBA, senior director of specialty strategy and innovation at Walgreens, discusses the potential impact of specialty medications on overall drug spending.
Advertisement
Michael Einodshofer, RPh, MBA, senior director of specialty strategy and innovation at Walgreens, discusses the potential impact of specialty medications on overall drug spending.
This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
3
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5